Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | GRB2 | P62993 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 2/20 | 0.55 |
| ▸ | NOS1 | P29475 | 2/20 | 0.55 |
| ▸ | NOS2 | P35228 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557134 | 1.00 | HTR2A (0.64) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| SCHEMBL503602 | 1.00 | HTR2A (0.64) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| SCHEMBL44156 | 1.00 | HTR2A (0.64) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| SCHEMBL44155 | 1.00 | HTR2A (0.64) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| Hydrochloric Acid SCHEMBL10584250 | 0.98 | HTR2A (0.62) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| Hydrochloric Acid SCHEMBL6775624 | 0.98 | HTR2A (0.62) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| Hydrochloric Acid SCHEMBL6775619 | 0.98 | HTR2A (0.62) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| SCHEMBL6831079 | 0.88 | PPARG (0.60) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| SCHEMBL16131653 | 0.88 | HTR2A (0.69) | HTR2AHTR2CHTR2BEPHX1DPP4 | |
| SCHEMBL19943590 | 0.88 | HTR2A (0.69) | HTR2AHTR2CHTR2BEPHX1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245483-A1 | METHODS AND COMPOSITIONS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250361273-A1 | METHODS AND COMPOSITIONS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC | 2025-11-27 | — | — | US | disclosed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-118879592-A | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-11-01 | — | — | CN | disclosed |
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | disclosed |
| CN-118139868-A | Orally bioavailable nucleoside analogs | 维纳拓尔斯制药公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-4355755-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2024043250-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-111182880-B | WNT compositions and process from serum-free culture conditions | 安卡萨再生疗法公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-114761026-A | Compositions and methods for in vivo synthesis of non-native polypeptides | 斯克利普斯研究所 | 2022-07-15 | — | — | CN | disclosed |
| CN-114746099-A | Eukaryotic semisynthetic organisms | 斯克利普斯研究所 | 2022-07-12 | — | — | CN | disclosed |
| CN-112500466-B | Peptidomimetic macrocycles | 艾瑞朗医疗公司 | 2022-05-03 | — | — | CN | disclosed |
| EP-3983543-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | The Scripps Research Institute (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3976635-A1 | METHODS OF TREATING HYPERLIPIDEMIA CONDITIONS WITH NETRIN-1 COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-108348571-B | Peptidomimetic macrocycles and uses thereof | 艾瑞朗医疗公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114206911-A | Methods of treating hyperlipidemia disorders with axon-targeting factor-1 compounds | 加利福尼亚大学董事会 | 2022-03-18 | — | — | CN | disclosed |
| CN-114207129-A | Agents and methods for replication, transcription and translation in semi-synthetic organisms | 斯克利普斯研究所 | 2022-03-18 | — | — | CN | disclosed |
| CN-114173878-A | Peptidomimetic macrocycles and uses thereof | 艾瑞朗医疗公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361273-A1 | METHODS AND COMPOSITIONS | MC4R, GPR119, MC2R | HTR2A 219/4885HTR2C 265/4885HTR2B 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.